FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2070791276> ?p ?o ?g. }

• W2070791276 abstract "The purpose of this pilot study was to determine the maximum tolerated dose of alpha-2a interferon given by subcutaneous injection and combined with high dose pelvic radiation for locally advanced or recurrent rectal cancer.In this Phase I pilot study, patients with locally advanced, unresectable, or recurrent rectal cancer with or without distant metastases received external beam pelvic radiotherapy over 5 to 6 weeks combined with escalating doses of alpha-2a interferon. Interferon was escalated in increments of 3 million units for each patient cohort, starting at 3 million units subcutaneously 3 days weekly during pelvic radiation. Radiotherapy consisted of 44 Gy (2 Gy fractions) to the pelvis followed by a boost of 6 Gy or 16 Gy to gross pelvic tumor, depending on the presence or absence of small bowel in the boost field, respectively. Between 1991 and 1993, 10 patients were treated on this study, five with locally advanced and five with locally recurrent rectal cancer.At 6 million units of interferon, Grade 3 (WHO criteria) toxicities were as follows: diarrhea (one), leukopenia (one), and neutropenia (one). One patient died of a massive GI bleed at this dose level. Death was not felt to be treatment related. The maximum tolerated dose of interferon was 3 million units three times weekly with radiation. Three patients had unusual complications at 4, 6, and 6 months possibly related to treatment. The first had a right distal ureteric stricture with a right urinoma. The second had a sudden left foot drop that has remained stable. The third had sudden onset of bilateral lower extremity paraplegia with spontaneous resolution.The maximally tolerated dose of interferon alpha-2a given three times weekly during pelvic radiation was 3 million units based on acute side effects. Nevertheless, even at this dose level there were three unusual subacute complications possibly related to treatment. Caution is advised when combining interferon alpha-2a with high dose pelvic radiation, especially in patients with predisposing conditions (such as diabetes) for radiotherapy complications." @default.
• W2070791276 created "2016-06-24" @default.
• W2070791276 creator A5000695802 @default.
• W2070791276 creator A5003482181 @default.
• W2070791276 creator A5007443740 @default.
• W2070791276 creator A5015323594 @default.
• W2070791276 creator A5043468818 @default.
• W2070791276 creator A5045767721 @default.
• W2070791276 date "1997-01-01" @default.
• W2070791276 modified "2023-09-26" @default.
• W2070791276 title "A Phase I pilot study of pelvic radiation and alpha-2a interferon in patients with locally advanced or recurrent rectal cancer" @default.
• W2070791276 cites W138695865 @default.
• W2070791276 cites W1629970388 @default.
• W2070791276 cites W1848897569 @default.
• W2070791276 cites W1964663612 @default.
• W2070791276 cites W1965247814 @default.
• W2070791276 cites W1967658581 @default.
• W2070791276 cites W1968132100 @default.
• W2070791276 cites W1971294331 @default.
• W2070791276 cites W1972373303 @default.
• W2070791276 cites W1973785201 @default.
• W2070791276 cites W1975380299 @default.
• W2070791276 cites W1978031188 @default.
• W2070791276 cites W1994949219 @default.
• W2070791276 cites W2000453698 @default.
• W2070791276 cites W2000581687 @default.
• W2070791276 cites W2001366629 @default.
• W2070791276 cites W2003530585 @default.
• W2070791276 cites W2003540193 @default.
• W2070791276 cites W2016732259 @default.
• W2070791276 cites W201840217 @default.
• W2070791276 cites W2020930081 @default.
• W2070791276 cites W2024332851 @default.
• W2070791276 cites W2026043900 @default.
• W2070791276 cites W2026892879 @default.
• W2070791276 cites W2028890735 @default.
• W2070791276 cites W2030569579 @default.
• W2070791276 cites W2030689003 @default.
• W2070791276 cites W2031327905 @default.
• W2070791276 cites W2033573484 @default.
• W2070791276 cites W2035799645 @default.
• W2070791276 cites W2043067191 @default.
• W2070791276 cites W2043691565 @default.
• W2070791276 cites W2044793874 @default.
• W2070791276 cites W2051646162 @default.
• W2070791276 cites W2058703572 @default.
• W2070791276 cites W2060584454 @default.
• W2070791276 cites W2066723521 @default.
• W2070791276 cites W2067903799 @default.
• W2070791276 cites W2068049913 @default.
• W2070791276 cites W2071155580 @default.
• W2070791276 cites W2081773523 @default.
• W2070791276 cites W2097512974 @default.
• W2070791276 cites W2100195894 @default.
• W2070791276 cites W2110313794 @default.
• W2070791276 cites W2112254107 @default.
• W2070791276 cites W2125701475 @default.
• W2070791276 cites W2159461712 @default.
• W2070791276 cites W2163052390 @default.
• W2070791276 cites W2167805334 @default.
• W2070791276 cites W2233184797 @default.
• W2070791276 cites W2276517358 @default.
• W2070791276 cites W2394637014 @default.
• W2070791276 cites W2401201987 @default.
• W2070791276 cites W2409183596 @default.
• W2070791276 cites W2409860816 @default.
• W2070791276 cites W2466997009 @default.
• W2070791276 doi "https://doi.org/10.1016/s0360-3016(96)00515-9" @default.
• W2070791276 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9069300" @default.
• W2070791276 hasPublicationYear "1997" @default.
• W2070791276 type Work @default.
• W2070791276 sameAs 2070791276 @default.
• W2070791276 citedByCount "5" @default.
• W2070791276 countsByYear W20707912762020 @default.
• W2070791276 crossrefType "journal-article" @default.
• W2070791276 hasAuthorship W2070791276A5000695802 @default.
• W2070791276 hasAuthorship W2070791276A5003482181 @default.
• W2070791276 hasAuthorship W2070791276A5007443740 @default.
• W2070791276 hasAuthorship W2070791276A5015323594 @default.
• W2070791276 hasAuthorship W2070791276A5043468818 @default.
• W2070791276 hasAuthorship W2070791276A5045767721 @default.
• W2070791276 hasConcept C121608353 @default.
• W2070791276 hasConcept C126322002 @default.
• W2070791276 hasConcept C126838900 @default.
• W2070791276 hasConcept C141071460 @default.
• W2070791276 hasConcept C159047783 @default.
• W2070791276 hasConcept C2776178377 @default.
• W2070791276 hasConcept C2776694085 @default.
• W2070791276 hasConcept C2777063308 @default.
• W2070791276 hasConcept C2778357063 @default.
• W2070791276 hasConcept C2780873365 @default.
• W2070791276 hasConcept C2781074409 @default.
• W2070791276 hasConcept C2909179924 @default.
• W2070791276 hasConcept C509974204 @default.
• W2070791276 hasConcept C526805850 @default.
• W2070791276 hasConcept C71924100 @default.
• W2070791276 hasConceptScore W2070791276C121608353 @default.
• W2070791276 hasConceptScore W2070791276C126322002 @default.
• W2070791276 hasConceptScore W2070791276C126838900 @default.
• W2070791276 hasConceptScore W2070791276C141071460 @default.

• next